FULL-LENGTH ORIGINAL RESEARCH
The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials
Article first published online: 10 JUL 2012
Wiley Periodicals, Inc. © 2012 International League Against Epilepsy
Volume 54, Issue 1, pages 66–74, January 2013
How to Cite
Zaccara, G., Perucca, P., Loiacono, G., Giovannelli, F. and Verrotti, A. (2013), The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials. Epilepsia, 54: 66–74. doi: 10.1111/j.1528-1167.2012.03589.x
- Issue published online: 3 JAN 2013
- Article first published online: 10 JUL 2012
- Accepted May 24, 2012; Early View publication July 10, 2012.
Data S1. Flow diagram of trials.
Data S2. Characteristics of studies included in the meta-analysis.
Data S3. Flow diagram of the selection processof adverse events (AEs).
Data S4. Risk differences (99% CIs) for adverse events associated with at least one dose of LCM. Significant estimates are shown in bold.
Figure S1. Number needed to harm at LCM dosesof 200, 400, and 600 mg for the AEs fatigue, nausea, vomitingand tremor, which were significantly associated with at least onedose of the experimental drug.
Figure S2. Frequency of AEs among patients randomized to placebo.
|epi3589_sm_DocumentS1.doc||29K||Supporting info item|
|epi3589_sm_DocumentS2.doc||86K||Supporting info item|
|epi3589_sm_DocumentS3.doc||29K||Supporting info item|
|epi3589_sm_DocumentS4.doc||34K||Supporting info item|
|epi3589_sm_FigS1.tif||799K||Supporting info item|
|epi3589_sm_FigS2.tif||808K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.